

Resource Summary Report

Generated by [RRID](#) on Aug 19, 2026

MSCV-Myc-IRES-RFP

RRID:Addgene_35395
Type: Plasmid

Proper Citation

RRID:Addgene_35395

Plasmid Information

URL: <http://www.addgene.org/35395>

Proper Citation: RRID:Addgene_35395

Insert Name: Myc

Organism: Mus musculus

Bacterial Resistance: Ampicillin

Defining Citation: [PMID:22340591](#)

Vector Backbone Description: Vector Backbone:MSCV; Vector Types:Mammalian Expression, Retroviral; Bacterial Resistance:Ampicillin

Plasmid Name: MSCV-Myc-IRES-RFP

Record Creation Time: 20220422T222151+0000

Record Last Update: 20260815T081400+0000

Ratings and Alerts

No rating or validation information has been found for MSCV-Myc-IRES-RFP.

No alerts have been found for MSCV-Myc-IRES-RFP.

Data and Source Information

Source: [Addgene](#)

Usage and Citation Metrics

We found 8 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Wang W, et al. (2025) Chromatin modification abnormalities by CHD7 and KMT2C loss promote medulloblastoma progression. *Cell reports*, 44(5), 115673.

Patterson DG, et al. (2021) An IRF4-MYC-mTORC1 Integrated Pathway Controls Cell Growth and the Proliferative Capacity of Activated B Cells during B Cell Differentiation In Vivo. *Journal of immunology (Baltimore, Md. : 1950)*, 207(7), 1798.

Schepers A, et al. (2021) Identification of Autophagy-Related Genes as Targets for Senescence Induction Using a Customizable CRISPR-Based Suicide Switch Screen. *Molecular cancer research : MCR*, 19(10), 1613.

Lopusna K, et al. (2021) Dnmt3b catalytic activity is critical for its tumour suppressor function in lymphomagenesis and is associated with c-Met oncogenic signalling. *EBioMedicine*, 63, 103191.

Guo L, et al. (2020) A combination strategy targeting enhancer plasticity exerts synergistic lethality against BETi-resistant leukemia cells. *Nature communications*, 11(1), 740.

Luong-Gardiol N, et al. (2019) β -Catenin-Dependent Signals Maintain BCR-ABL1+ B Cell Acute Lymphoblastic Leukemia. *Cancer cell*, 35(4), 649.

Kim MJ, et al. (2018) PAF-Myc-Controlled Cell Stemness Is Required for Intestinal Regeneration and Tumorigenesis. *Developmental cell*, 44(5), 582.

Wirth M, et al. (2014) MYC and EGR1 synergize to trigger tumor cell death by controlling NOXA and BIM transcription upon treatment with the proteasome inhibitor bortezomib. *Nucleic acids research*, 42(16), 10433.